NTLA vs VRTX
NTLA and VRTX side by side — valuation & fundamentals (public data).
Key statistics
| Metric | NTLAINTELLIA THERAPEUTICS, INC. | VRTXVERTEX PHARMACEUTICALS INC / MA |
|---|---|---|
| Market cap | $1.50B | $119.77B |
| P/E (TTM) | — | 28.0 |
| P/B | — | 6.19 |
| P/S | 22.1x | 10.0x |
| Revenue | — | $12.22B(TTM) |
| Revenue growth (YoY) | 16.9% | 8.9% |
| Net income | — | $4.34B(TTM) |
| Earnings growth (YoY) | 20.5% | 838.1% |
| EPS, diluted | — | $16.85(TTM) |
| EBIT margin | -651.7% | 34.8% |
| ROE | -66.5% | 20.4% |
| ROIC | — | 25.4% |
| 1y total return | -6.7% | +2.0% |
Figures from SEC filings · for reference only · not investment advice
Crecimiento de $10,000: NTLA frente a VRTX
| Métrica | NTLA | VRTX |
|---|---|---|
| Valor final | $4.9K | $55.1K |
| Retorno total | -51.5% | +450.6% |
| CAGR | -6.8% | +18.1% |
| Volatilidad | 78.4% | 32.8% |
| Sharpe | 0.25 | 0.56 |
| Sortino | 0.37 | 0.82 |
| Caída máxima | -96.5% | -41.6% |
Basado en 2574 días de negociación comunes, 2016-05-06 → 2026-08-03 · tasa libre de riesgo 3.83% (bono corto del Tesoro actual, mantenido constante)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)